Please assess the completion status of the following clinical trial:

Trial Title: A Phase II Clinical Trial of Hydronidone Capsules(F351) in Patients With Liver Fibrosis Induced by HBV Chronic Hepatitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~1. Aged 18-65, all genders.~2. History of chronic hepatitis B, HBsAg positive≧six months.~3. ALT\<eight-fold ULN (maximum).~4. Significant liver fibrosis confirmed by liver biopsy.~5. HBeAg positive patients, HBV DNA\>2.0×104 IU/mL (copies/mL); HBeAg negative patients，HBV DNA\>2.0×103 IU/mL (104copies/mL).~6. Having not accepted the antiviral therapy with interferon and/or nucleoside analog.~7. Having not taken anti-inflammatory drugs to protect liver within 1 month before selection.~8. Capable of understanding and signing the informed consent before the study.~Exclusion Criteria:~1. Failing to meet any one requirement of the inclusion criteria.~2. Having suffered massive hemorrhage of gastrointestinal tract within 3 months before selection~3. TBiL\>three-fold ULN.~4. AFP\>100 ug/L~5. PLT≦60×109/L~6. PTA\<50%~7. Having obvious space-occupying lesion in liver as shown by B ultrasound examination.~8. With a portal vein ≧1.2cm wide as shown by B ultrasound examination.~9. BMI index\>30.~10. The patient who suffered from liver function decompensation hepatic cirrhosis and liver neoplasms.~11. The patient with alcoholic, drug-induced, hereditary, immune and other viral and non- viral chronic hepatitis.~12. The patient with angiocarpy, lung, kidney, incretion, nerve and blood system disease and mental disease.~13. The patient with active peptic ulcer.~14. Gestational and breast feeding women.~15. The subject is the legal disabled person according to the Law of the People's Republic of China on the Protection of Disabled Persons of the April 2008 edition.~16. The subject who participated in other drug tests within recent 3 months.~17. The patient who is suspected with poor compliance or disagrees to participate in the test.~18. The patient who is considered by other investigators not to be suitable for participating in the study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Hydronidone(180mg) & Entecavir & Placebo (Type: EXPERIMENTAL): hydronidone capsule 30mg/capsule hydronidone capsule, three times a day, 2 capsules each time; with co-administration of placebo capsule, three times a day, 2 capsules each time, namely the daily dose of the investigational product is 180mg.~The test groups and the control group take the entecavir capsule which is orally taken for antiviral therapy, one time a day, 0.5mg each time, oral administration on an empty stomach.
- Hydronidone(270mg) & Entecavir & Placebo (Type: EXPERIMENTAL): hydronidone capsule 30mg/capsule hydronidone capsule, three times a day, 3 capsules each time; with co-administration of placebo capsule, three times a day, 1 capsules each time, namely the daily dose of the investigational product is 270mg.~The test groups and the control group take the entecavir capsule which is orally taken for antiviral therapy, one time a day, 0.5mg each time, oral administration on an empty stomach.
- Hydronidone(360mg) & Entecavir (Type: EXPERIMENTAL): hydronidone capsule 30mg/capsule hydronidone capsule, three times a day, 4 capsules each time; namely the daily dose of the investigational product is 360mg.~The test groups and the control group take the entecavir capsule which is orally taken for antiviral therapy, one time a day, 0.5mg each time, oral administration on an empty stomach.
- Entecavir & Placebo(360mg) (Type: EXPERIMENTAL): placebo capsule 30mg/capsule placebo capsule, three times a day, 4 capsules each time. The test groups and the control group take the entecavir capsule which is orally taken for antiviral therapy, one time a day, 0.5mg each time, oral administration on an empty stomach.

Based on this trial design, predict the completion outcome and termination type (if applicable).